Participants 0 156 4
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
Participants 202 334 3
n Aug 10, 2009, more than 35% of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
Participants 750 841 3
 patients with tuberous sclerosis complex who had SEGA that was growing and needed treatmen
Participants 1701 1833 8
f the original 117 randomly assigned patients, 111 were given everolimus between Aug 20, 2009, and Jan 11, 2013 (date of data cutoff
